2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)Blood Protein Disorders, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingPhase 22026-10-05NCT04728893
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-08-28NCT06428396